pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ultragenyx Pharmaceutical Inc. ($RARE) · news · pharmadog
← back to Ultragenyx Pharmaceutical Inc.
News mentioning $RARE
837
stories
Jul 1, 26
BridgeBio gets funding for drug launch; United buys into cell therapy
biopharma dive
Jul 1, 26
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
biopharma dive
Jul 1, 26
STAT+: More signs that GLP-1s may help with peripheral artery disease
stat
Jul 1, 26
FDA says Zyn can market its pouches as safer than cigarettes
stat
Jul 1, 26
STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch
stat
Jul 1, 26
Opinion: What Ebola and Marburg are teaching us about the next pandemic
stat
Jun 30, 26
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
biopharma dive
Jun 30, 26
These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.
biopharma dive
Jun 30, 26
Top FDA gene and cell therapy regulator to step down
biopharma dive
Jun 30, 26
Opinion: Florida is the first state to require EKGs for high school athletes. It’s a mistake
stat
Jun 29, 26
FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturing
fda press
Jun 29, 26
Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone disease
endpoints
Jun 29, 26
Theravance, after clinical setbacks, agrees to $929M buyout
biopharma dive
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 26, 26
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
biopharma dive
Jun 26, 26
On second try, Acadia drug gets nod from European regulators
biopharma dive
Jun 25, 26
De-Risking a Rare Disease Launch Starts with Precision
fiercebiotech
Jun 20, 26
Endpoints News History: 10 Years, Bootstrap to FT
endpoints
Jun 19, 26
Federal grant delays could jeopardize essential disability services, research
stat
Jun 18, 26
Moderna flu vaccine wins unanimous support from FDA panel
biopharma dive
Jun 18, 26
New hope in treating Huntington’s disease and a report card on RFK Jr.’s promises
stat
Jun 18, 26
Ebola cases increase almost 40% in a week as death toll passes 200
stat
Jun 17, 26
UniQure to file gene therapy for approval, reflecting major shifts at FDA
biopharma dive
Jun 15, 26
FDA plans to keep Makary priorities on trials, China, deputy says
endpoints
Jun 15, 26
Covid vaccination cut risk of adverse heart events, large study finds
stat
Jun 15, 26
Lilly scores early positive data for new JAK drug
biopharma dive
Jun 13, 26
STAT+: FDA approves Sanofi diabetes drug for children with stage 3 diabetes
stat
Jun 13, 26
WHO director-general is profoundly concerned after visit to Ebola outbreak area
stat
Jun 12, 26
Amgen and the FDA want two different outcomes for Tavneos. What will patients do?
endpoints
Jun 12, 26
Biopharma's pay oddities of 2025: Executive perks and eccentricities
endpoints
← prev
page 22 of 28
next →
